1. Home
  2. NICE guidance
  3. In development

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]

In development [GID-TA10825] Expected publication date: 10 August 2022

  • Project information
  • Project documents

Documents

A list of downloadable documents created during development.

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 329 KB 14 July 2022  
  • Committee papers PDF 877 KB 14 July 2022  
  • Public committee slides PDF 1.38 MB 14 July 2022  

Draft guidance: 1

  • Draft guidance: 1  
  • Appraisal consultation document (PDF version) PDF 309 KB 31 March 2022  
  • Committee papers PDF 6.79 MB 31 March 2022  
  • Appraisal consultation document (online commenting)  

Invitation to participate

  • Equality impact assessment (Scoping) PDF 124 KB 17 May 2021  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 287 KB 17 May 2021  
  • Final stakeholder list PDF 186 KB 17 May 2021  
  • Final scope PDF 256 KB 17 May 2021